Pharmaceutical Technology

MAY 24, 2023

Our board and management team believe that the combined company will be well-positioned to develop powerful new therapies with the potential to overcome resistance to current immunotherapies, an area of significant unmet need.” Morphogenesis’ lead personalised cancer vaccine, IFx-Hu2.0,

Gene Therapy 130

Gene Therapy In-Vivo In-Vitro Immune Response 130

XTalks

SEPTEMBER 30, 2020

The research shows that the activity of the immune messenger type 1 interferon (IFN) protein is diminished, either by genetic mutations or an autoimmune attack by neutralizing antibodies against it, in a subset of COVID-19 patients. Related: Low T Cell Counts Observed in COVID-19 Patients. Mutational Errors in COVID-19 Patients.

Antibody 135

Antibody Genetics Research In-Vitro 135

The Pharma Data

AUGUST 15, 2021

Even as several safe and effective COVID-19 vaccines are being administered to people worldwide, scientists are still hard at work developing different vaccine strategies that could provide even stronger or longer-lasting immunity against SARS-CoV-2 and its variants.

Protein 52

Protein Vaccination Vaccine Antibody 52

XTalks

NOVEMBER 20, 2020

A new type of test based on detection of activated T cells may prove to have greater utility in determining whether someone has had a COVID-19 infection compared to a traditional antibody test. Researchers at Adaptive Biotechnologies compared T-Detect to a commercial antibody test from DiaSorin on samples obtained from people in Vo’, Italy.

Antibody 98

Antibody Immune Response Protein In-Vitro 98

XTalks

JANUARY 27, 2021

COVID-19 vaccine maker Moderna announced this week that results from a study show that the shot is effective against some of the new circulating variants of SARS-CoV-2. In a news release from Moderna, the company reported that the administration of its COVID-19 vaccine induced antibody titers against both variants.

Vaccination 52

Vaccination Vaccine In-Vitro Protein 52

The Pharma Data

MARCH 25, 2022

AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination, has been recommended for marketing authorisation in the European Union (EU) for the pre-exposure prophylaxis (prevention) of COVID-19 in a broad population of adults and adolescents aged 12 years and older weighing at least 40 kg.

Antibody 52

Antibody In-Vivo Medicine Vaccination 52

The Pharma Data

MARCH 29, 2022

Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months Evusheld retains neutralising activity against the Omicron BA.2 2 subvariant, now the dominant strain in Europe. 1-3 Evusheld was generally well-tolerated in the trial. Christoph D.

Antibody 52

Antibody In-Vivo Vaccination Vaccine 52

Delveinsight

JANUARY 12, 2021

Medivir AB has entered into an exclusive licensing agreement with IGM Biosciences to receive global, exclusive development rights for Birinapant. It is an IgM antibody targeting Death Receptor 5 (DR5), and IGM is hoping to test Birinapant with IGM-8444 for the treatment of solid cancers later this year. R on macrophages.

Licensing 52

Licensing Licensing Antibody Gene Therapy 52

XTalks

MARCH 11, 2021

Amidst initial confusion, fear and chaos, masks and social distancing quickly became new norms, and now vaccines are leading hope for a way out. With vaccine shortages and slow rollouts in many parts of the world, the COVID-19 way of life continues in many places. As of March 11, 2021, COVID-19 has claimed the lives of over 2.6

Vaccination 98

Vaccination Vaccine In-Vitro Antibody 98

The Pharma Data

MAY 17, 2021

The European Commission’s Medical Device Coordination Group (MDCG) sent a notice to in vitro diagnostic (IVD) makers and their authorized representatives reminding them of their obligation to assess the impact of COVID-19 variants on the performance of their tests. . Posted 17 May 2021 | By Michael Mezher .

In-Vitro 52

In-Vitro Manufacturing Vaccination Vaccine 52

Roots Analysis

AUGUST 15, 2023

Overview of Cell Free Systems Cell-free systems are ­in-vitro platforms which allow occurrence of biochemical reactions in the absence of living cells. It is worth mentioning that the first reconstituted system, Protein Synthesis Using Recombinant Elements (PURE) , was developed in 2001.

Protein 52

Protein In-Vitro Production Reagent 52

Drug Discovery World

FEBRUARY 16, 2024

New drug discovery and development concepts The event started with a panel discussion on new drug discovery and development concepts and tools in cancer research. Another factor he mentioned is that drug development is focused on an efficacy versus effectiveness problem, which Rombotis also mentioned.

Research 52

Research In-Vitro Drugs Vaccination 52

pharmaphorum

JANUARY 17, 2023

Research into mRNA dates back to the 1970s, but with the approval of both Moderna and BioNTech/Pfizer’s vaccines, this approach has finally been validated. At the end of last year, the UK government entered into a partnership with the company, which saw Moderna agree to provide 250 million vaccine doses per year over the course of a decade.

Vaccination 93

Vaccination Vaccine In-Vivo In-Vitro 93

Pfizer

JANUARY 27, 2023

In the ongoing development of the Pfizer-BioNTech COVID-19 vaccine, Pfizer has not conducted gain of function or directed evolution research. This research provides a way for us to rapidly assess the ability of an existing vaccine to induce antibodies that neutralize a newly identified variant of concern.

Research 112

Research Vaccination Vaccine Drugs 112

Drug Discovery World

MAY 25, 2023

Following the Scottish Research and Drug Development Forum meeting, DDW’s Diana Spencer provides a snapshot of drug discovery in Scotland. With over 150 pharma services/supply companies and 19 universities, Scotland is one of the most advanced life science sectors in the UK and the world.

Research 52

Research Drugs In-Vitro Insulin 52

The Pharma Data

JANUARY 16, 2021

It has become the de facto standard equipment for high titer transient protein expression platforms used by many leading Chinese antibody drug pharmaceutical companies and IVD (In Vitro Diagnostics) companies since its launch in Oct. Etta Biotech is a leading cell electroporation technology and equipment supplier. About Etta Biotech.

Protein 52

Protein Production Antibody In-Vitro 52

XTalks

DECEMBER 19, 2023

1) Comirnaty (COVID-19 Vaccine, mRNA) Sales in 2022: $37.81 Why it did so well: The COVID-19 pandemic was one of the major drivers for Comirnaty sales in the US in 2022 as it remained the vaccine of choice throughout the pandemic. The rise of the Omicron variant fuelled the sale of the vaccine. billion in sales in 2022.

Sales 64

Sales FDA Approval Drugs Vaccination 64

The Pharma Data

MARCH 16, 2021

Accurate detection and differentiation of SARS-CoV-2 mutations can help assess the spread of circulating variants and monitor their potential impact on therapeutics, vaccines and public health interventions. 1.1.7), South Africa (B.1.351), 1.351), and Brazil (P.1). Variants of B.1.1.7, 1.351 and P.1 Viruses naturally evolve over time.

Antibody 52

Antibody Clinical Trials Clinical Trials Vaccination 52

pharmaphorum

DECEMBER 15, 2022

Stefan Woxström is the new senior vice president for Europe and Canada at AstraZeneca, moving over from the company’s Japanese division to take over from Iskra Reic , who will now serve as EVP of vaccines and immune therapies. The month of November saw a number of notable hires and personnel moves in biotech and pharma. More CEO shakeups.

Sales 52

Sales In-Vitro Antibody Drug Delivery 52

XTalks

SEPTEMBER 14, 2020

“Vaccine Nationalism” Could Prove the Undoing of COVID-19 Containment. Tension is mounting as nations big and small jockey around industry to ensure they are first in line to access a vaccine, should one prove to be successful against COVID-19. Moderna’s COVID-19 Vaccine. The price of that prize is incalculable.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92

The Pharma Data

JULY 23, 2021

The antibody combination was granted a Special Approval Pathway under article 14-3 of the Pharmaceuticals and Medical Devices Act. Roche’s Chief Medical Officer and Head of Global Product Development. Roche’s Chief Medical Officer and Head of Global Product Development. About Ronapreve (casirivimab and imdevimab).

Antibody 52

Antibody Medicine Production In-Vitro 52

The Pharma Data

NOVEMBER 29, 2021

About LENVIMA ® (lenvatinib); available as 10 mg and 4 mg capsules LENVIMA, discovered and developed by Eisai, is a multiple receptor tyrosine kinase asset that inhibits the kinase conditioning of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4).

In-Vitro 52

In-Vitro Containment Development Medicine 52

Drug Discovery World

NOVEMBER 16, 2022

Think of a cell culture, where scientists can observe the growth of a cell in the body in an in-vitro setting, and gain an understanding of how they react to different drug compounds. Organoids are developed using pluripotent stem cells (PSCs) or adult stem cells in a 3D culture matrix, and mimic organs in the human body. .

Drugs 97

Drugs In-Vivo In-Vitro Scientist 97

The Pharma Data

NOVEMBER 11, 2021

“With cases in Europe surging, it’s vital that people have access to different approaches, in addition to vaccines, that reduce the complaint burden, and Ronapreve has demonstrated efficacity in treating and precluding COVID-19 and against variants of concern,” said Levi Garraway,M.D.,Ph.D.,

In-Vitro 40

In-Vitro Antibody Medicine Development 40

The Pharma Data

DECEMBER 9, 2020

Uniquely positioned in the rapidly evolving local biotech ecosystem in China in addition to an expansive global presence, Overland will strategically partner to jointly develop innovative, novel therapeutics. We look forward to developing and advancing our differentiated pipeline of novel therapeutics in carefully selected disease areas.”.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

Pharmaceutical Technology

SEPTEMBER 10, 2008

The first activities of the company concerned the pre-clinical toxicological testing of several new candidate molecules showing cytostatic activity, initially developed by a former research institute, as well as the breeding and supplying of laboratory animals. . It will most probably lead to a new anti-flu vaccine.

In-Vitro 130

In-Vitro Genotoxicity In-Vivo Clinical Research 130

The Pharma Data

NOVEMBER 12, 2021

Roche’s Chief Medical Officer and Head of Global Product Development. Although vaccinations are adding encyclopedically, Europe is entering a fourth surge of rising cases and treatment options for the full range of complaint inflexibility and variants of concern are still demanded.

In-Vitro 40

In-Vitro Medicine Development Marketing 40

The Pharma Data

JUNE 26, 2021

“Even with the availability of vaccines and declines in deaths from COVID-19 in various parts of the world, we continue to see new hospitalisations from severe forms of the disease,” said Levi Garraway, M.D., Roche’s Chief Medical Officer and Head of Global Product Development. FDA in this setting, but the U.S.

Clinical Trials 40

Clinical Trials Clinical Trials In-Vitro Antibody 40

Pharmaceutical Technology

AUGUST 26, 2008

“It has to be recognised that antibody therapy does not fit everyone and that small molecule therapy may be more appropriate for some people due to cost considerations.” It was once derided as the stuff of science fiction, but in recent years, biotechnology has emerged as an important growth area in pharmaceuticals.

Antibody 130

Antibody Licensing Licensing Production 130

Drug Discovery World

JULY 22, 2022

To mitigate these risks, clinicians are turning to other immunomodulators, such as cell-based therapies, bispecific antibodies, and cytokine treatments. Immune checkpoint inhibitors (ICIs) like pembrolizumab (Keytruda) have numerous benefits and have become a standard of treatment for many patients. Jespersen et al.

In-Vivo 52

In-Vivo Engineer In-Vitro Antibody 52

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.

Antibody 64

Antibody Engineer Protein Scientist 64

pharmaphorum

OCTOBER 5, 2022

The US Government’s Biomedical Advanced Research and Development Authority (BARDA) has made an initial investment of approximately $55 million for rapid development of VIR-2482, the Vir Biotechnology’s investigational prophylactic monoclonal antibody (mAb) for seasonal and pandemic influenza viruses.

Antibody 104

Antibody In-Vitro Radiology Development 104

The Pharma Data

NOVEMBER 17, 2021

Nasdaq VIR) moment blazoned US government contracts totalling roughly$ 1 billion (1) (USD) to buy sotrovimab, an investigational monoclonal antibody for the early treatment of COVID-19, which the US Food and Drug Administration (FDA) granted Exigency Use Authorization (EUA) in May 2021. 1.617.2), Delta Plus (AY.1 2) and Mu (B.1.621).

Antibody 52

Antibody In-Vitro Vaccination Vaccine 52

Drug Discovery World

FEBRUARY 1, 2024

This paid-for advertorial by Twist Bioscience appeared in the Therapeutic Antibodies Guide – DDW Volume 25 – Issue 1, Winter 2023/2024 Improving gene synthesis speed can reduce workflow times, saving you invaluable time, says Twist Bioscience. Traditionally, therapeutic antibody discovery is labour and resource intensive.

Antibody 64

Antibody Gene Protein Manufacturing 64

The Pharma Data

NOVEMBER 18, 2021

New data from the AZD7442 COVID-19 PROVENT forestallment and Paraphernalia inpatient treatment Phase III trials both showed robust efficacity from a one- time intramuscular (IM) cure of the long- amusement antibody (LAAB) combination. About 2 of the global population is considered at increased threat of an shy response to a COVID-19 vaccine.1

Trials 52

Trials Antibody In-Vitro Vaccination 52

Drug Discovery World

FEBRUARY 15, 2023

Further discovery of PD-1 and CTLA4 as negative immune regulators led to the development of a new class of cancer therapeutics, namely the immune checkpoint inhibitors 5,6. Between 2017 and 2020, the number of IO therapies being developed has increased significantly from 2030 (for 265 targets) to 4,720 (for 504 targets).

Research 52

Research In-Vitro In-Vivo Development 52

The Pharma Data

MARCH 26, 2021

The FDA EUA submission is based on an interim analysis of efficacy and safety data from the Phase 3 COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial – Intent to Care Early) trial, which evaluated VIR-7831 as monotherapy for the early treatment of COVID-19 in adults at high risk of hospitalisation.

Antibody 52

Antibody Trials Vaccination Vaccine 52